全文获取类型
收费全文 | 3594篇 |
免费 | 284篇 |
国内免费 | 29篇 |
专业分类
耳鼻咽喉 | 25篇 |
儿科学 | 158篇 |
妇产科学 | 79篇 |
基础医学 | 564篇 |
口腔科学 | 31篇 |
临床医学 | 264篇 |
内科学 | 857篇 |
皮肤病学 | 132篇 |
神经病学 | 536篇 |
特种医学 | 92篇 |
外科学 | 225篇 |
综合类 | 1篇 |
一般理论 | 1篇 |
预防医学 | 224篇 |
眼科学 | 33篇 |
药学 | 256篇 |
中国医学 | 9篇 |
肿瘤学 | 420篇 |
出版年
2024年 | 8篇 |
2023年 | 41篇 |
2022年 | 93篇 |
2021年 | 131篇 |
2020年 | 98篇 |
2019年 | 117篇 |
2018年 | 123篇 |
2017年 | 102篇 |
2016年 | 124篇 |
2015年 | 153篇 |
2014年 | 168篇 |
2013年 | 211篇 |
2012年 | 285篇 |
2011年 | 294篇 |
2010年 | 180篇 |
2009年 | 141篇 |
2008年 | 253篇 |
2007年 | 247篇 |
2006年 | 249篇 |
2005年 | 222篇 |
2004年 | 180篇 |
2003年 | 171篇 |
2002年 | 136篇 |
2001年 | 17篇 |
2000年 | 13篇 |
1999年 | 20篇 |
1998年 | 23篇 |
1997年 | 18篇 |
1996年 | 13篇 |
1995年 | 7篇 |
1994年 | 7篇 |
1993年 | 11篇 |
1992年 | 3篇 |
1991年 | 4篇 |
1990年 | 5篇 |
1989年 | 3篇 |
1988年 | 5篇 |
1987年 | 2篇 |
1986年 | 4篇 |
1985年 | 2篇 |
1984年 | 5篇 |
1983年 | 4篇 |
1982年 | 3篇 |
1976年 | 1篇 |
1972年 | 1篇 |
1971年 | 2篇 |
1970年 | 1篇 |
1969年 | 2篇 |
1968年 | 1篇 |
1966年 | 1篇 |
排序方式: 共有3907条查询结果,搜索用时 15 毫秒
61.
62.
Fulvio Bruni Anna Laura Pasqui Marcello Pastorelli Giovanni Bova Michela Cercignani Alberto Palazzuoli Tatsuya Sawamura W R Gioffre Alberto Auteri Luca Puccetti 《Clinical and applied thrombosis/hemostasis》2005,11(4):417-428
Hydroxymethyl-glutaryl-CoA-reductase inhibitors (statins) reduce cardiovascular mortality by decreasing cholesterol as well as by non-lipid-related actions. Oxidized low-density lipoproteins (ox-LDL) are pro-atherogenic molecules and potent platelet agonists. CD36 and lectin-like ox-LDL receptor-1 (LOX-1) are specific ox-LDL receptors also expressed in platelets. This study was planned to address whether treatment with atorvastatin 10 mg/day, pravastatin 40 mg/day or simvastatin 20 mg/day could affect platelet CD36 and LOX-1 expression. Twenty-four patients for each treatment were evaluated after 3, 6, and 9 days and at 6 weeks for complete lipid profile (chromogenic), ox-LDL (ELISA), platelet P-selectin (P-sel), CD36, LOX-1 (FACS), and intracellular citrullin recovery (iCit) (HPLC). Data show hyperactivated platelets (P-sel absolute values, percent variation in activated cells, all p < 0.001), and CD36 and LOX-1 overexpression (all p < 0.001) in patients at baseline. P-sel, CD36, and LOX-1 were significantly decreased by atorvastatin and simvastatin (all p < 0.01) and related with iCit increase (r = 0.58, p < 0.001) and platelet-associated ox-LDL (r = 0.51, p < 0.01) at 9 days. Pravastatin reduced LOX-1 and P-sel (p < 0.05) at 6 weeks in relation with decreased LDL and ox-LDL (r = 0.39, p < 0.01 and r = 0.37, p < 0.01, respectively). These data suggest that atorvastatin and simvastatin reduce platelet activity by exposure of CD36 and LOX-1 before significant LDL reduction, whereas pravastatin action is detected later and in relation with LDL and ox-LDL lowering. Rapid and consistent reduction of CD36 and LOX-1 could be considered a direct anti-atherothrombotic mechanism related to the role of ox-LDL in platelet activation, platelet-endothelium interactions, and NO synthase activity. 相似文献
63.
CTCF functions as a critical regulator of cell-cycle arrest and death after ligation of the B cell receptor on immature B cells
下载免费PDF全文
![点击此处可从《Proceedings of the National Academy of Sciences of the United States of America》网站下载免费的PDF全文](/ch/ext_images/free.gif)
64.
Ghyslaine Bruna Djeunang Dongho Karthigayan Gunalan Mariangela LEpiscopia Giacomo Maria Paganotti Michela Menegon Rose Efeutmecheh Sangong Georges Bouting Mayaka Joseph Fondop Carlo Severini Martin Sanou Sobze Louis H. Miller Gianluca Russo 《The American journal of tropical medicine and hygiene》2021,104(3):987
65.
Antiepileptic drug prescribing before,during and after pregnancy: a study in seven European regions
下载免费PDF全文
![点击此处可从《Pharmacoepidemiology and drug safety》网站下载免费的PDF全文](/ch/ext_images/free.gif)
66.
67.
68.
69.
Russo D Malagola M de Vivo A Fiacchini M Martinelli G Piccaluga PP Damiani D Candoni A Michielutti A Castelli M Testoni N Ottaviani E Rondoni M Pricolo G Mazza P Zuffa E Zaccaria A Raspadori D Bocchia M Lauria F Bonini A Avanzini P Gugliotta L Visani G Fanin R Baccarani M 《British journal of haematology》2005,131(2):172-179
Fludarabine plus cytarabine (Ara-C) and idarubicin (FLAI) is an effective and well-tolerated induction regimen for the treatment of acute myeloid leukaemia (AML). This phase III trial compared the efficacy and toxicity of FLAI versus idarubicin plus Ara-C and etoposide (ICE) in 112 newly diagnosed AML patients <60 years. Fifty-seven patients received FLAI, as the first induction-remission course, and 55 patients received ICE. Post-induction treatment consisted of high-dose Ara-C (HDAC). After HDAC, patients in complete remission (CR) received a second consolidation course (mitoxantrone, etoposide, Ara-C) and autologous stem cell transplantation (auto-SCT) or allogeneic (allo)-SCT, according to the age, disease risk and donor availability. After a single induction course, CR rate was 74% in the FLAI arm and 51% in the ICE arm (P = 0.01), while death during induction was 2% and 9% respectively. Both haematological (P = 0.002) and non-haematological (P = 0.0001) toxicities, especially gastrointestinal (i.e. nausea, vomiting, mucositis and diarrhoea), were significantly lower in FLAI arm. In both arms, relapses were more frequent in patients who were not submitted to allo-SCT. After a median follow-up of 17 months, 30% and 38% of the patients are in continuous CR in FLAI and ICE arm respectively. Our prospective randomised study confirmed the anti-leukaemic effect and the low toxic profile of FLAI as induction treatment for newly diagnosed AML patients. 相似文献
70.
New insights into the pharmacokinetics of intravenous busulfan in children with sickle cell anemia undergoing bone marrow transplantation
下载免费PDF全文
![点击此处可从《Pediatric blood & cancer》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Javid Gaziev MD Antonella Isgrò MD Alessia Francesca Mozzi PhD Aurèlie Petain PhD Laurent Nguyen MD Cristiano Ialongo MD PhD Vincenzo Dinallo PhD Pietro Sodani MD Marco Marziali MD Marco Andreani PhD Manuela Testi PhD Katia Paciaroni MD Cristiano Gallucci MD Gioia De Angelis MD Cecilia Alfieri MD Michela Ribersani MD Guido Lucarelli MD 《Pediatric blood & cancer》2015,62(4):680-686